Good
Partially Aligned
Patient Risk:
Info
Summary
Most naming/ingredient-content claims are generally consistent with label concepts provided (pantoprazole as active ingredient; PPI concept; existence of formulation for oral suspension and mention of IV/injectable labeling excerpts). However, the supplied label excerpts do not substantiate multiple claims about brand-name mapping (e.g., Protonix/Protonix IV usage by route), country-dependent branding, and do not explicitly describe what varies between generic and brand products as stated.
Category Scores
Accurate Statements
Pantoprazole is the generic drug name.
Label concept reviewed is pantoprazole sodium as the active drug substance (no explicit statement about 'generic drug name' wording).
Generic pantoprazole and the brand Protonix both contain the same active ingredient (pantoprazole).
Label excerpts provided describe pantoprazole sodium (pantoprazole sodium sesquihydrate) as the active ingredient; brand-name equivalence to Protonix is not explicitly stated in the excerpts.
Differences between generic pantoprazole and brand Protonix, if any, come from inactive ingredients and formulation details.
Not directly stated in the provided label excerpts.
Unsupported Statements
Protonix is a common brand name for pantoprazole (oral).
The provided label excerpts do not explicitly identify Protonix as the brand name for pantoprazole (oral).
Protonix IV is a brand name for pantoprazole (intravenous form).
The provided label excerpts mention an injectable labeling excerpt, but do not explicitly map 'Protonix IV' to pantoprazole IV by brand name.
Pantoprazole is marketed under multiple brand labels depending on the country and whether it is oral or IV.
No country- or multiple-brand marketing claims are supported by the supplied label excerpts.
Protonix is typically used for oral pantoprazole.
The supplied label excerpts do not connect Protonix specifically to oral pantoprazole use.
Protonix IV refers to the intravenous form of pantoprazole.
The supplied label excerpts do not explicitly define 'Protonix IV' as the IV form.
Differences between generic pantoprazole and brand Protonix, if any, come from inactive ingredients and formulation details.
The supplied label excerpts do not discuss comparative inactive ingredients or differences between generic and brand products.
Contradictions
Important Omissions
None material to the specific claims evaluated; however, the label excerpts provided did not include explicit boxed-warning content, detailed interaction specifics beyond selected examples, or an explicit brand-name mapping for Protonix/Protonix IV.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The evaluated claims are primarily about naming/brand mapping and active ingredient equivalence; the label excerpts support pantoprazole sodium as the active drug but do not substantiate several brand/route-mapping claims. Unsupported brand/route mapping could create confusion if used to select a formulation, but no direct dosing/safety directive was provided in the claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims about Protonix/Protonix IV brand naming and route association are not supported by the supplied prescribing information excerpts.
Suggested Improvement
Limit statements to what the label excerpts explicitly support (e.g., pantoprazole sodium active ingredient; oral delayed-release suspension administration restrictions). Remove or qualify brand-name/route mapping claims unless directly supported by the provided label text.